原发性肝癌经肝动脉化疗栓塞生存三年以上20例临床分析

PRIMARY HEPATIC CARCINOMA TREATED BY CHEMOEMBOLIZATION──A Clinical Analysis of 20 Cases with Survival Period Longer than 3 Years

原发性肝癌经肝动脉化疗栓塞（ＴＡＥ）１１０例，存活３年以上者２０例，占ＴＡＥ治疗的１８．２％；存活４年者７例，占６３％，＞５年者４例，占３．６％。对失去手术机会的中晚期肝癌，ＴＡＥ为首选姑息疗法。提高疗效，延长生存期的重要因素是：患者基础肝功能良好；单一巨块型、直径＜１０ｃｍ；合理安排栓塞间隔期；及时处理并发症和积极治疗肝内外转移灶。

Abstract Advanced primary hepatic carcinoma was treated in 110 patients by percuaneous transhepatic arteri-al chemoembolization (TAE)from January 1987 to October 1989 according to Seldinge’s protocolwith mitomycin C,Adriamycin or carboplatin and 40%iodized oil.The treatment was given once every4～12 weeks and the number of treatment for each patient varied from 2 to 19 depending on patients’condition and response.Of the 110 patients ,20 survived>3years,among which 7 survived>4 yearsand 4survived >5 years.Following treatment,a greater than 50%reduction of tumor size was observed in 13 cases and a decrease in AFP to normal level in 12 cases.Seven patients were treated with TAEfollowed by tumor resection and,2 patients were treated with TAE due to recurrence after tumorresection 11 patients were treated with TAE alone.The mean survival period was 53.1 and 43.5months,respectively.TAE is considered as the first choice of palliative treatment for patients with advanced hepatic carcinoma.Factors that might influence the result of TAE treatment are discussed .